Anika Therapeutics Form 4: William Jellison Boosts Ownership via RSUs
Rhea-AI Filing Summary
Anika Therapeutics (ANIK) – Form 4 insider filing: Director William R. Jellison reported the grant of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts to one common share upon vesting, which will occur in full at the earlier of the company’s 2026 annual meeting or 20 June 2026. Following the award, Jellison’s direct ownership rises to 20,403 common shares; he also holds 2,700 shares indirectly through a revocable trust. No shares were sold or disposed of, and the grant was made at $0 cost, reflecting a routine, equity-based director compensation transaction.
Positive
- 14,164 RSUs granted to director, lifting direct ownership to 20,403 shares and signaling continued insider alignment with shareholders.
Negative
- None.
Insights
TL;DR: Routine Form 4 shows director granted 14,164 RSUs, boosting direct stake to 20,403 shares; no sales—neutral impact.
This filing reflects Anika’s standard director equity program. The award modestly increases insider alignment but does not involve open-market buying or selling. With no accompanying operational data or market purchase, the event is informational rather than materially price-moving. Investors may view continued board ownership positively, yet the absolute share count is small relative to ANIK’s float, limiting valuation impact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14,164 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Consists of shares transferred by Mr. Jellison to the Amended and Restated William R. Jellison Trust dated July 3, 2018, of which Mr. Jellison is a beneficiary and trustee.
